Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Kodiak Sciences Inc
K27Current price
5.19 EUR
+0.025 EUR (+0.48%)
Last closed
5.5 USD
Company
kodiak.com
ISIN
US50015M1099
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
258 864 336 USD
Yield for 12 month
+162.38 %
1Y
3Y
5Y
10Y
15Y
K27
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. Address: 1200 Page Mill Road, Palo Alto, CA, United States, 94304
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
2.75 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-25 947 000 USD
Last Year
-11 001 000 USD
Current Quarter
-6 681 000 USD
Last Quarter
-6 646 000 USD
Key Figures K27
1 year
3 years
5 years
10 years
EBITDA
-192 783 008 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-26.72 %
PEG Ratio
–
Return On Equity TTM
-71.5 %
Wall Street Target Price
2.75 USD
Revenue TTM
–
Book Value
4.09 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-3.77 USD
Diluted Eps TTM
-3.77 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics K27
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History K27
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation K27
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-0.1181
Price Book MRQ
1.2043
Financials K27
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators K27
For 52 weeks
1.75 USD
7.77 USD
50 Day MA
3.06 USD
Shares Short Prior Month
1 541 705
200 Day MA
3.63 USD
Short Ratio
9.05
Shares Short
1 426 822
Short Percent
4.4 %
BeatStart